Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
HypertensionImpaired Glucose Tolerance
Interventions
DRUG

AR9281

AR9281 taken in BID dosing regimen for 28 days

DRUG

AR9281

AR9281 taken in TID dosing regimen for 28 days

DRUG

Placebo

Placebo taken in BID dosing regimen for 28 days

DRUG

Placebo

Placebo taken in TID dosing regimen for 28 days

Trial Locations (30)

30066

Arete Investigational site, Marietta

32127

Arete Investigational site, Port Orange

32216

Arete Investigational site, Jacksonville

32720

Arete Investigational site, DeLand

33026

Arete Investigational site, Pembroke Pines

33169

Arete Investigational site, Miami

33606

Arete Investigational site, Tampa

33770

Arete Investigational site, Largo

34203

Arete Investigational site, Bradenton

34652

Arete Investigational site, New Port Richey

35662

Arete Investigational site, Muscle Shoals

36617

Arete Investigational site, Mobile

40213

Arete Investigational site, Louisville

43302

Arete Investigational site, Marion

43338

Arete investigational site, Mount Gilead

45219

Arete Investigational site, Cincinnati

45245

Arete Investigational site, Cincinnati

49079

Arete Investigational site, Paw Paw

60101

Arete Investigational site, Addison

73132

Arete Investigational site, Oklahoma City

75251

Arete Investigational site, Dallas

78229

Arete Investigational site, San Antonio

78704

Arete Investigational site, Austin

84058

Arete Investigational site, Orem

89123

Arete Investigational site, Las Vegas

91345

Arete Investigational site, Mission Hills

92801

Arete Investigational site, Anaheim

94520

Arete Investigational site, Concord

97404

Arete Investigational site, Eugene

02301

Arete Investigational site, Brockton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Arete Therapeutics

INDUSTRY

NCT00847899 - Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance | Biotech Hunter | Biotech Hunter